Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKōichi Goto, Pasi A. Jänne, Sang‐We Kim et al.|Journal of Clinical Oncology|2023Cited by 293
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinibKiichiro Ninomiya, Katsuyuki Kiura|Scientific Reports|2018Cited by 47